Cost-effectiveness of Nivolumab + Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer in England
Neoadjuvant nivolumab + PDC is a highly cost-effective treatment for nmNSCLC. The findings of this model supported positive reimbursement decisions for neoadjuvant nivolumab + PDC from NICE.
Authors
- James Brockbank (ORCID: https://orcid.org/0000-0002-5349-6017)
- Thor‐Henrik Brodtkorb (ORCID: https://orcid.org/0000-0002-9899-233X)
- Stefano Lucherini (ORCID: https://orcid.org/0000-0001-6410-6865)
- Ariel Sun (ORCID: https://orcid.org/0000-0002-3576-935X)
- Sandra Milev (ORCID: https://orcid.org/0000-0002-6962-7157)
- Joel W. Russell (ORCID: https://orcid.org/0000-0001-8620-3770)
- Benjamin White (ORCID: https://orcid.org/0000-0002-8705-7581)
- M. Harris
- Lien Vo
Institutions
- Bristol-Myers Squibb (United States) (US)
- RTI Health Solutions (US)
- Uddevalla sjukhus (SE)
- Bristol-Myers Squibb (United Kingdom) (GB)
- Thermo Fisher Scientific (United States) (US)
- Bristol-Myers Squibb (Italy) (IT)
- Thermo Fisher Scientific (Israel) (IL)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-11-15
- DOI
- https://doi.org/10.1007/s40487-025-00397-5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00